Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies — Carla Nester (2022) | RDL Network
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Article 2022 en
Authors
CN
Carla Nester
GA
Gerald B. Appel
AB
Andrew S. Bomback
Abstract
1 min read
While demonstrating a favorable safety profile, danicopan resulted in incomplete and inadequately sustained inhibition of AP, probably due to limitations in its PK/PD profile in C3G, leading to lack of efficacy. Complete and sustained AP inhibition is required for a clinical response in patients with C3G.
Carla Nester, Steven D. Podos, Jonathan Hogan, Gerald B. Appel, Andrew S. Bomback, Koen Bouman, Terry Cook, Erica Daina, Bradley P. Dixon, Craig B. Langman, Liz Lightstone, Jane A. Thanassi, Kara Rice, Mingjun Huang, Samir M. Parikh, Matthew C. Pickering, John Sperati, Howard Trachtman, James A. Tumlin, Jack F.M. Wetzels, Giuseppe Remuzzi
Marina Vivarelli, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri
Carla Nester, Ute Eisenberger, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Manuel Praga, Giuseppe Remuzzi, María José Soler Romeo, Junhao Liu, Matthias Meier, Nicholas J.A. Webb, Edwin Wong
Carla Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.